Radiopharm Theranostics reported a gross margin of -38.23% and a net margin of -293.49% for the quarter ended Jun 2026. These financial ratios cover 5 quarters of results from Jun 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Jun2023 | Jun2024 | Dec2024 | Jun2025 | Jun2026 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross Margin | 9.92% | -5,206.31% | -38.23% | ||
| EBT Margin | -20,214.28% | -56,455.32% | -293.49% | ||
| EBIT Margin | -111.24% | -56,358.92% | -293.49% | ||
| EBITDA Margin | -109.14% | -56,351.99% | -291.35% | ||
| Operating Margin | -19,942.70% | -56,358.92% | -293.49% | ||
| Net Margin | -111.24% | -56,302.83% | -293.49% | ||
| Efficiency | |||||
| Assets AverageAssets Avg. | 46.46M | 46.50M | 0.49M | ||
| Invested CapitalInvested Cap. | 0.40M | 81.55M | 0.48M | 0.34M | |
| Leverage & Solvency | |||||
| Interest Coverage RatioInterest Cover | 400.59 | 0.41 | 584.59 | ||
| Debt Ratio | 0.46 | 0.32 | 0.37 | 0.43 | |
| Times Interest Earned | 400.59 | 0.41 | 584.59 | ||
| Return Ratios | |||||
| Return on Sales [ROS]ROS | -111.24% | -56,358.92% | -293.49% | ||
| Return on Capital Employed [ROCE]ROCE | -20,674.70% | ||||
| Return on Assets [ROA]ROA | -15,023.32% |